Diabetes and obesity - Issue 1/2024
Editorial
Reviews
13
Integration of glycemic compensation markers, including glycemic variability in patients with diabetes mellitus
Oliver Viktor Rácz, Eva Lovásová, Jaroslava Nováková, Adriana Phillipiová
25
Inklisiran and its role in lipid-lowering therapy
Olga Bobelová
33
Slovak Diabetes Society recommendations for diabetes education
Marek Macko Vedúci Autorského Kolektívu, Andrea Bukovská, Peter Galajda, Marián Mokáň, Zbynek Schroner, Za Výbor Slovenskej Diabetologickej Spoločnosti
36
Type 2 diabetes mellitus and obesity – dangerous companions
Zbynek Schroner
41
53
62
Long-term sustainability of metabolic compensation in telemedicine use – results of 18 months follow-up
Jozef Lacka, Pavol Košík, Klaudia Mesíková
70
Diabetic distress from clinical diabetology view
Daniel Kolény, Marcela Murínová
News
78
80
Pilot project for early detection of hyperglycemia, prediabetes and/or diabetes mellitus in insured persons of VšZP, a.s., and throughout Slovakia in specialist outpatient clinics of diabetologists in diabetes-naïve patients: report
Katarína Černá, Viera Doničová, Adriana Ilavská, Zbynek Schroner
82
News
88
Diabetics from all over Slovakia on reconditioning stays
Jozef Borovka
Diabetes and obesity
2024 Číslo 1
Najčítanejšie v tomto čísle
- Early use of SGLT2-inhibitors i in the treatment of type 2 diabetes mellitus
- Current position of GLP-1 receptor agonists in type 2 diabetes mellitus treatment
- Metformin in the treatment of type 2 diabetes mellitus and its current position
- Coexistence of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of a patient with type 2 diabetes mellitus